Summary#
This bill changes how Medicare sets payment rates for most clinical diagnostic laboratory tests that are not advanced diagnostic tests (non-ADLTs). It requires Medicare to use final, market-based private payor payment data from a large, independent nonprofit claims database for many widely available tests, and it changes timing, definitions, and fallback payment rules when data are missing. The stated goal is more accurate and stable Medicare payments for lab tests so beneficiaries can keep access to testing.
- Main change: For widely available non-ADLT tests, CMS must contract with a qualifying independent nonprofit claims-data entity to supply final private-payor payment rates and volumes for use in Medicare’s private payor-based fee schedule starting with data collection periods in 2028.
- Data standards: The qualifying database must be independent, nonprofit, nationally representative, validated, include at least 50 billion claims from more than 50 private payors/administrators, and cover all 50 states and DC.
- Final payment rates: The bill defines “final payment rate” (last payment made, excluding denied, appealed, error, or recouped payments) and requires CMS to use those final rates when available.
- Fallback rules: If CMS cannot contract with a qualifying entity or there is no data for a widely available test, Medicare payments for a specified period will be maintained and then increased by the Consumer Price Index for all urban consumers (CPI-U) until data are available. For non-widely available tests with no data, CMS may “cross-walk” to a comparable test or use gapfilling rules.
- Transparency and timing: CMS must publish an explanation of payment rates and supporting data. The bill shifts several timing dates to 2027–2028 and requires CMS rulemaking parameters by December 31, 2026.
What is unclear: The bill sets standards and a contracting requirement but does not specify how CMS will choose among qualifying entities if more than one applies, or how costs of the contract will be handled.
What it means for you#
- Patients / Medicare beneficiaries
- This aims to keep lab testing available by basing Medicare payments on more complete market data. It does not change patient cost-sharing rules directly.
- Clinical laboratories
- Medicare may use different, more market-based payment amounts for widely available tests once the contracted database provides data. Labs could see more stable or different payment rates than under current rules.
- Labs that previously reported private-payor data themselves may report less for widely available tests because CMS will rely on the contracted database.
- Private insurers and claims-data organizations
- A large independent nonprofit claims database that meets the bill’s standards would be asked to report final payment rates and volumes to CMS under contract.
- Private payors included in that database will indirectly influence Medicare rates through the dataset.
- Medicare administrators (CMS)
- CMS must contract with a qualifying entity, adopt new data definitions and timelines, publish explanations of payment rates, and complete rulemaking by late 2026 for 2027 data collection periods.
- Small or specialized test providers
- For tests that are not “widely available,” the bill keeps or clarifies existing gapfilling and cross-walking processes when no private-payor data are reported.
Expenses#
No publicly available information.
- Possible administrative costs (inferred from the bill): CMS will need staff time and systems for contracting, vetting and certifying the qualifying entity, collecting and using the database, and producing public explanations.
- Possible costs to the qualifying entity and private payors: maintaining validated, version-controlled national claims data and providing reports under contract may require staffing and technology investments.
- Possible Medicare spending effects (uncertain): the fallback rule using CPI-U or limits on payment reductions could raise or stabilize Medicare payments for some tests, but the bill contains no cost estimate.
Proponents' View#
- The bill appears intended to make Medicare lab payment rates more accurate by using final private-payor payment information rather than provisional or self-reported rates.
- Supporters may argue that using a large, validated, independent claims database will produce payment rates that better reflect the national market and reduce sudden payment shocks that could disrupt patient access.
- Requiring publication of payment explanations could increase transparency and help laboratories check the accuracy of CMS calculations.
- The fallback CPI-U adjustment provides a predictable short-term payment rule when no market data are available.
- Extending timelines and adjusting reduction limits may provide longer-term payment stability for laboratories.
Opponents' View#
- One concern is reliance on a single contracted nonprofit database: the bill does not explain how CMS will select among multiple qualified entities or whether relying on one source could bias results.
- The database requirements (for example, 50 billion claims and more than 50 payors) are strict and may limit which organizations qualify, possibly delaying implementation or excluding some market segments.
- The bill does not explain how privacy and data-sharing costs or burdens on private payors will be handled.
- Using CPI-U as a fallback could prevent timely downward adjustments to payments that reflect changing market prices, potentially increasing Medicare spending for some tests.
- It is unclear how much the contract and additional CMS work will cost, and no fiscal estimate is provided in the bill text.